joae tirzepatide glp-1 FDA says shortage of drug is over GLP-1 Essentials™ (Tirzepatide) – ADEPT
Description
While effective for blood sugar control, it does not produce the same level of appetite suppression or weight loss as semaglutide or tirzepatide
THE WAY FORWARD Cynthia Rothblum-Oviatt, USA Barbara Pietrucha, Poland William Davis, UK
How is Wegovy administered
GLP-1 agonism: Reduces appetite, slows gastric emptying, promotes satiety GIP agonism: Enhances insulin secretion, may reduce GLP-1-related nausea Glucagon agonism: Increases hepatic glucose output control, drives thermogenesis and energy expenditure Phase 2 clinical trial data published in 2023 showed subjects lost an average of 24.2% of body weight over 48 weeks making it arguably the most potent weight-loss compound currently known
Like for example, the reduction of inflammatory markers is occurring even before the weight loss that starts to manifest
